Medical Department, Lilly S.A, Alcobendas, Madrid, Spain.
Real Life Data, Badalona, Barcelona, Spain.
Curr Med Res Opin. 2020 Sep;36(9):1449-1456. doi: 10.1080/03007995.2020.1793749. Epub 2020 Jul 23.
To compare healthcare resource use (HRU) and annual costs in type 2 diabetes mellitus (T2DM) patients with poor glycaemic control and obesity versus good glycaemic control without obesity.
Observational retrospective study based on the analysis of electronic medical records from the BIG-PAC database, with one year of follow-up. T2DM patients aged ≥30 years who requested medical care during 2013 were included. Annual HRU and costs per patient were compared between a reference group (HbA1c ≥ 8%, BMI ≥30 kg/m, receiving ≥2 oral antidiabetic drugs [OADs]) and a control group (HbA1c < 7% and BMI <30 kg/m). Direct and indirect costs (lost productivity) were analysed. Cost comparisons across groups were made using the analysis of covariance (ANCOVA) for each cost component, with age, sex, time from diagnosis, Charlson comorbidity index, OAD number and sex by group interaction as covariates.
During the follow-up, patients in the reference group ( = 2709) had a greater HRU than those in the control group ( = 5266), especially in the number of primary care (PC) visits (11.8 vs. 9.8; 95%CI: 11.5-12.1 vs. 9.6-10.0) and days of hospitalization (1.1 vs 0.6; 95%CI: 1.0-1.2 vs. 0.5-0.7). The main components of the total cost were hospital admissions (24.5%), productivity losses (16.3%), complementary tests (14.4%), PC visits (14.2%) and medication (13.6%) in the reference group and medication (19.6%), hospital admissions (18.7%) and PC visits (18.2%) in the control group. The corrected mean annual cost per patient was higher in the reference than in the control group: €1804 vs. €1309; < .001.
Poor glycaemic control and obesity in T2DM patients were associated with increased HRU and costs in routine clinical practice.
比较血糖控制不佳伴肥胖的 2 型糖尿病(T2DM)患者与血糖控制良好且不肥胖的患者的医疗资源利用(HRU)和年度成本。
基于 BIG-PAC 数据库电子病历的回顾性观察研究,随访时间为 1 年。纳入 2013 年就诊的年龄≥30 岁、接受治疗的 T2DM 患者。将 HbA1c≥8%、BMI≥30kg/m2、接受≥2 种口服降糖药(OAD)的患者设为参考组,HbA1c<7%且 BMI<30kg/m2 的患者设为对照组,比较两组患者的年度 HRU 和每位患者的年度成本。分析直接和间接成本(生产力损失)。采用协方差分析(ANCOVA)比较各组间各成本构成的差异,年龄、性别、诊断后时间、Charlson 合并症指数、OAD 数量和组间交互作用为协变量。
随访期间,参考组(n=2709)患者的 HRU 明显高于对照组(n=5266),尤其是初级保健(PC)就诊次数(11.8 次 vs. 9.8 次;95%CI:11.5-12.1 次 vs. 9.6-10.0 次)和住院天数(1.1 天 vs. 0.6 天;95%CI:1.0-1.2 天 vs. 0.5-0.7 天)。参考组总费用的主要构成部分是住院治疗(24.5%)、生产力损失(16.3%)、补充检查(14.4%)、PC 就诊(14.2%)和药物治疗(13.6%),对照组的主要构成部分是药物治疗(19.6%)、住院治疗(18.7%)和 PC 就诊(18.2%)。校正后参考组患者的年度人均费用明显高于对照组:€1804 vs. €1309;<.001。
T2DM 患者血糖控制不佳伴肥胖与常规临床实践中 HRU 和费用的增加相关。